companydirectorylist.com  Global Business Directories and Company Directories
Search Business,Company,Industry :


Country Lists
USA Company Directories
Canada Business Lists
Australia Business Directories
France Company Lists
Italy Company Lists
Spain Company Directories
Switzerland Business Lists
Austria Company Directories
Belgium Business Directories
Hong Kong Company Lists
China Business Lists
Taiwan Company Lists
United Arab Emirates Company Directories


Industry Catalogs
USA Industry Directories














  • Jubbonti® (denosumab-bbdz) | Official Patient Site
    Jubbonti® is FDA-approved for people with osteoporosis, steroid-induced bone loss, or bone loss from breast or prostate cancer hormone therapy See full ISI and PI for safety info
  • Jubbonti: Uses, Dosage, Side Effects, Warnings - Drugs. com
    Jubbonti (denosumab-bbdz) is an injection that is administered subcutaneously (under the skin) once every 6 months by a healthcare provider to treat osteoporosis in postmenopausal women at high risk for fracture, to treat glucocorticoid-induced osteoporos
  • label - accessdata. fda. gov
    Jubbonti is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk
  • Denosumab-bbdz (subcutaneous route) - Mayo Clinic
    Denosumab-bbdz injection is used to treat osteoporosis (thinning of the bones) in women who have an increased risk for fractures after menopause, and osteoporosis in men It is given when other medicines cannot be used or after other medicines did not work well
  • Jubbonti - European Medicines Agency (EMA)
    Jubbonti is a medicine used to treat the following conditions: osteoporosis (a disease that makes bones fragile) in women who have been through the menopause and in men who have an increased risk of fracture (broken bones)
  • Jubbonti (Denosumab-bbdz Injection): Side Effects, Uses . . . - RxList
    Jubbonti is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy
  • Jubbonti® (denosumab-bbdz) | Official HCP Website
    Jubbonti® (denosumab-bbdz) is the first and only biosimilar interchangeable with Prolia® (denosumab) See full ISI and PI for safety info
  • Jubbonti 60 mg mL subcutaneous syringe - Kaiser Permanente
    Denosumab is used to treat bone loss (osteoporosis) in people who have a high risk of getting fractures Osteoporosis causes bones to become thinner and break more easily




Business Directories,Company Directories
Business Directories,Company Directories copyright ©2005-2012 
disclaimer